Rigel(RIGL)
Search documents
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Prnewswire· 2025-01-09 13:05
FDA Designations and Development Progress - The US FDA granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS), highlighting the unmet medical need for patients with this rare disorder [1][2] - R289 also received Fast Track designation for the treatment of previously-treated transfusion-dependent lower-risk MDS patients [3] - The ongoing Phase 1b study of R289 is evaluating its safety, tolerability, pharmacokinetics, and preliminary activity in patients with lower-risk MDS who are relapsed or refractory to prior therapies [1] R289 Mechanism and Potential - R289 is a prodrug of R835, a dual inhibitor of IRAK1 and IRAK4, which blocks inflammatory cytokine production in response to TLR and IL-1R signaling [4] - Chronic stimulation of TLR and IL-1R pathways is thought to cause the pro-inflammatory environment in the bone marrow responsible for persistent cytopenias in lower-risk MDS patients [4] - Initial data from the Phase 1b study of R289 in lower-risk MDS patients is encouraging, supporting its potential as a new treatment option [2] Company Overview - Rigel Pharmaceuticals is a biotechnology company focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer [5] - Founded in 1996, Rigel is based in South San Francisco, California, and is listed on the Nasdaq under the ticker RIGL [5]
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Prnewswire· 2025-01-08 13:05
SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA. To access the live webcast or archived recording, visit the Investor Relations sectio ...
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Prnewswire· 2025-01-03 13:05
SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 46,131 stock options to eight non-executive employees vestin ...
Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents
Seeking Alpha· 2024-12-30 13:30
When I first covered Rigel Pharmaceuticals (NASDAQ: RIGL ) back in April, I felt that they were considerably undervalued considering their then-recent acquisition of an important lung cancer targeted therapy, in addition to having an important IDH1 inhibitor growingI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your ...
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
ZACKS· 2024-11-19 15:56
Shares of Rigel Pharmaceuticals (RIGL) have gained 53.5% over the past four weeks to close the last trading session at $22.74, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $29.17 indicates a potential upside of 28.3%.The mean estimate comprises six short-term price targets with a standard deviation of $18.89. While the lowest estimate of $14 indicates a 38.4% decline from the ...
Rigel to Present at the Jefferies London Healthcare Conference
Prnewswire· 2024-11-12 13:05
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, at 9:30 am GMT (4:30 am EST).To access the live webcast or archived recording, visit the Investor Relations section of the company's website at ww ...
Rigel(RIGL) - 2024 Q3 - Earnings Call Transcript
2024-11-08 03:25
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kalpit Patel - B. Riley Securities Farzin Haque - Jefferies Operator Greetings an ...
Rigel(RIGL) - 2024 Q3 - Earnings Call Presentation
2024-11-08 00:44
1 Q3 2024 Financial Results Presentation November 7, 2024 Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, expected commercial and financial results; Rigel's ability to earn and receive milestone payments; expectations related to the potential and market opportunity of REZLIDHIA® (olutasidenib) as therapeutics for relapsed or refractory acute myeloid leukemi ...
Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates
ZACKS· 2024-11-07 23:21
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.30 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6,900%. A quarter ago, it was expected that this drug developer would post a loss of $0.37 per share when it actually produced a loss of $0.06, delivering a surprise of 83.78%.Over the last four quarters, the com ...
Rigel(RIGL) - 2024 Q3 - Quarterly Results
2024-11-07 21:22
Exhibit 99.1 Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update · Third quarter total revenue of $55.3 million, which includes TAVALISSE net product sales of $26.3 million, REZLIDHIA net product sales of $5.5 million and GAVRETO net product sales of $7.1 million · Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indications in Japan, the Republic of Korea and Taiwan, recording an upfront cash payment of $10.0 million during the third ...